Reference - Detail
| RRC ID | 61024 |
|---|---|
| Author | Wang Y, Liu Y, Zhou C, Wang C, Zhang N, Cao D, Li Q, Wang Z. |
| Title | An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL. |
| Journal | Leuk Lymphoma |
| Abstract |
AKR1C3 overexpression has been reported in various types of cancers, including T-ALL. AST-006 (TH-3424), an AKR1C3-specific prodrug, was reported recently to have potent cytotoxicity against liver cancer cells overexpressing AKR1C3 and T-ALL. In this study, AST-006 demonstrated potent anti-tumor activity against different T-ALL cell lines in vitro and in vivo, including patient-derived xenograft (PDX) model. AST-006 also exhibited minimal cytotoxicity against primary human T-cells in vitro and lymphocytes in cynomolgus monkeys in vivo, indicating that AST-006 is a promising therapeutic for T-ALL. |
| Volume | 61(7) |
| Pages | 1660-1668 |
| Published | 2020-7-1 |
| DOI | 10.1080/10428194.2020.1728746 |
| PMID | 32091283 |
| MeSH | Aldo-Keto Reductase Family 1 Member C3 Antineoplastic Agents, Alkylating Cell Line, Tumor Humans Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* Prodrugs* / pharmacology Xenograft Model Antitumor Assays |
| IF | 2.969 |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | Patent(IFI CLAIMS) |
| Total number of mentions | 5 |
| Altmetric score changes over past 6months | 0.0 |
| Resource | |
| Human and Animal Cells | ATN-1(RCB1440) |